Abstract

NfL as a Predictor of GdE Lesions in Patients With Relapsing Multiple Sclerosis Treated With Ozanimod in the Phase 2 RADIANCE Trial (P1-3.012)

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call